Seattle, Wash.-based Dendreon has appointed three new members to its executive team:

Joe DePinto is joining Dendreon as executive vice president, global commercial operations and will be responsible for all sales, marketing, and market access teams in the U.S. and globally. He has spent the last 20 years commercializing and developing oncology products, his experience includes sales, marketing, strategic accounts, market access, and product development on the R&D side. DePinto has held other vice president positions at ImClone Systems (subsidiary of Eli Lilly), Abraxis Bioscience and Ortho Biotech Products.

Robert S. Poulton was named executive vice president, technical operations and will oversee Dendreon's global manufacturing, operations, logistics and quality functions. He brings more than two decades of manufacturing and operational experience to the executive team, having previously served Dendreon as its global head of quality. Previously, Poulton served in a number of vice president positions at Wyeth, GlaxoSmithKline and SmithKline Beecham.

Christine Mikail was appointed as executive vice president, corporate development, general counsel, secretary and will be responsible for legal, corporate development and government affairs at Dendreon. She has experience in high-growth business development, complex transaction structuring and negotiation, intellectual property and patent portfolio management, regulatory and clinical strategy, as well as public company representation. Mikail has served in vice president positions at Savient Pharmaceuticals and ImClone Systems (subsidiary of Eli Lilly), and has worked at the law firms of Reed Smith LLP, Lowenstein Sandler PC and Wilmer Hale.